Skip to main content
HR 6482 116th Congress House Health Asia Business expenses China Drug safety, medical device, and laboratory regulation Government information and archives Health care costs and insurance Health programs administration and funding Health technology, devices, supplies Income tax deductions Manufacturing Military medicine Military procurement, research, weapons development Prescription drugs Public contracts and procurement Trade restrictions Veterans' medical care

Protecting Our Pharmaceutical Supply Chain from China Act of 2020

Introduced: April 10, 2020 See on congress.gov
Sign in to write a letter Sign in to watch
This bill died when the 116th Congress ended
It never became law before the 116th Congress (2019–2020) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 4 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Jul 13, 2020
Referred to the Subcommittee on Oversight and Investigations.
Apr 10, 2020
Referred to the Subcommittee on Health.
Apr 10, 2020
Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, Armed Services, and Veterans' Affairs, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Apr 10, 2020
Introduced in House
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service

Protecting Our Pharmaceutical Supply Chain from China Act of 2020

This bill requires the federal government to maintain a registry of certain foreign-sourced drugs, prohibits federal health care programs from purchasing drugs containing Chinese ingredients, requires drugs to be labeled for country of origin, and offers domestic manufacturing facility tax incentives.

What's happening now July 13, 2020

Referred to the Subcommittee on Oversight and Investigations.

 Related & companion bills 2
  • S 3537 Identical bill Protecting Our Pharmaceutical Supply Chain from China Act of 2020
  • S 3635 Related bill Protecting Our Pharmaceutical Supply Chain from China Act of 2020
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 6
 Cosponsors 8
All 8 Republican 6
R
Turner, Michael R.
Ohio · Oct 27, 2020
 R
Baird, James R.
Indiana · Jul 1, 2020
 R
Biggs, Andy
Arizona · May 22, 2020
Hartzler, Vicky
· May 8, 2020
 R
Van Drew, Jefferson
New Jersey · Apr 28, 2020
 R
Budd, Ted
North Carolina · Apr 10, 2020
Cheney, Liz
· Apr 10, 2020
 R
Stefanik, Elise M.
New York · Apr 10, 2020
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 6482: Protecting Our Pharmaceutical Supply Chain from China Act of 2020. 116th Congress. Open America. https://openamerica.io/bill/116-HR-6482/
MLA
"H.R. 6482: Protecting Our Pharmaceutical Supply Chain from China Act of 2020." 116th Congress, 2026, Open America, https://openamerica.io/bill/116-HR-6482/.
Bluebook (legal)
H.R. 6482, 116th Cong. (2026), https://openamerica.io/bill/116-HR-6482/.
Markdown link
[H.R. 6482: Protecting Our Pharmaceutical Supply Chain from China Act of 2020](https://openamerica.io/bill/116-HR-6482/)
Report a problem